Abstract
SummaryFCA was similar or slightly superior in activity to CA with regard to antitumor effects when tested against the following experimental tumors: ascitic leukemia L-1210, sarcoma-180, Ehrlich solid carcinoma and mammary adenocarcinoma EO 771. FCA was appreciably more active on a mg/kg basis than CA with regard to its effect against the solid forms of leukemia L-1210 in both semi-isologous BDF1 and homologous albino mice, as well as against Walker carcinosarcoma 256. Both substances were without effect against the Flexner-Jobling carcinoma in rats. FCA and CA exerted similar degrees of antiviral activity against herpes simplex keratitis in the rabbit and vaccinia virus in rhesus monkey kidney cell cultures. Both substances were inactive in vivo and in vitro against the following RNA-containing viruses: Columbia SK, Coxsackie virus B1 (GP), and influenza A (PR8).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
